OncoIntelligenceTM, our proprietary AI-digital pathology platform, reports the first AI-Grade for breast cancer.

2.3 million women worldwide are affected by breast cancer every year¹. Standard histologic grading initiates the care pathway yet is inadequate, requiring reliance on further testing. Much of the world’s population lacks access to innovative breast cancer technologies resulting in suboptimal outcomes and poor quality of life.
PreciseBreast, created to standardize cancer care, eliminates the subjectivity and variability of histologic grade. Specific tumor morphology features are analyzed; results enable earlier assessment of recurrence risk and the likelihood of chemotherapy benefit²
PreciseBreast, designed for digitized specimen transfer from any region of the world, reduces logistical and financial barriers while delivering an objective, accurate and reliable AI-Grade in hours.
The use of subjective grading alone is discouraged.⁴ Levels of inter-observer variation can and should still be improved.⁵ Histologic grade includes pathologist-assigned tubule formation, nuclear pleomorphism, and mitotic count. Grading variability may have influenced adjuvant chemotherapy decisions in 30% of patients.⁶ ⁹

57-70%
pathologist inter & intra-observer variation⁷ ⁸
54.7%
of Grade 3 tumors are low risk²
25.9%
of Grade 2 tumors are high risk²
74.1%
of Grade 2 tumors are low risk²


OncoIntelligence assigns AI-Grade based on 7 morphologic features quantified and weighted in the algorithm:¹⁰
PreciseBreast® powers the process of diagnosis and cancer care planning for everyone.
Medical society partners
We are proud to work with some of the most important cancer associations and societies.

Please fill out the form below.